Effects of Conversion From Calcineurin Inhibitors to Sirolimus or Everolimus on Renal Function and Possible Mechanisms in Liver Transplant Recipients

被引:13
|
作者
Tsai, Kai-Fan [1 ,2 ]
Li, Lung-Chih [1 ,2 ,6 ]
Hsu, Chien-Ning [2 ,3 ,7 ]
Lin, Chih-Che [2 ,4 ]
Lin, Yu-Hung [2 ,4 ]
Cheng, Yu-Fan [2 ,5 ]
Wang, Chih-Chi [2 ,4 ]
Chen, Chao-Long [2 ,4 ]
机构
[1] Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Nephrol, 123 Da Pei Rd, Kaohsiung 833, Taiwan
[2] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan
[3] Kaohsiung Chang Gung Mem Hosp, Dept Pharm, Kaohsiung, Taiwan
[4] Kaohsiung Chang Gung Mem Hosp, Liver Transplant Ctr, Dept Surg, Kaohsiung, Taiwan
[5] Kaohsiung Chang Gung Mem Hosp, Dept Diagnost Radiol, Kaohsiung, Taiwan
[6] Kaohsiung Chang Gung Mem Hosp, Inst Translat Res Biomed, Kaohsiung, Taiwan
[7] Kaohsiung Med Univ, Sch Pharm, Kaohsiung, Taiwan
来源
JOURNAL OF CLINICAL PHARMACOLOGY | 2019年 / 59卷 / 03期
关键词
chronic kidney disease; liver transplantation; mTOR inhibitor; renal preservation; urinary biomarkers; CHRONIC KIDNEY-DISEASE; LIPOCALIN NGAL; RAPAMYCIN; TACROLIMUS; EFFICACY; INJURY; STAGE; IMMUNOSUPPRESSION; PROLIFERATION; NEPHROPATHY;
D O I
10.1002/jcph.1334
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Mammalian targets of rapamycin inhibitors (mTORIs), including sirolimus and everolimus, are used for minimizing calcineurin inhibitors after liver transplantation. However, head-to-head randomized comparisons of these 2 mTORIs are lacking. We assessed the differences in renoprotection and possible mechanisms between sirolimus and everolimus in liver transplant recipients. For this prospective cohort study, we recruited liver transplant recipients whose regimens were switched from tacrolimus to sirolimus or everolimus at a Taiwan medical center. Serial changes in estimated glomerular filtration rate (eGFR), urinary N-acetyl--D-glucosaminidase, neutrophil gelatinase-associated lipocalin, 8-hydroxy-2-deoxyguanosine, and transforming growth factor-1 during 1 year after mTORI conversion were compared within and between groups. In the 61 patients analyzed, no significant change in eGFR occurred within 12 months after conversion in both mTORI groups. Among patients with baseline eGFR <60 mL/min/1.73 m(2), eGFR improved at 6 months and 1 year after conversion (+12.3 and +12.0 mL/min/1.73 m(2), both P < .05). Urinary N-acetyl--D-glucosaminidase decreased in both sirolimus and everolimus groups at 6 months (-68.7 +/- 137.6 and -62.0 +/- 92.4 U/g creatinine, both P < .05), and the reduction of urinary neutrophil gelatinase-associated lipocalin was significant in the sirolimus group (-4345.1 +/- 7763.5 ng/g creatinine; P < .05). Neither transforming growth factor-1 nor 8-hydroxy-2 '-deoxyguanosine changed significantly. In conclusion, the renoprotective effect of mTORI conversion was significant in liver transplant recipients with renal insufficiency, which was similar for sirolimus and everolimus, in the first year and may be associated with ameliorated tubular injury. Available evidence remains insufficient to determine which mTORI conversion therapy is more effective in renoprotection in the long run.
引用
收藏
页码:326 / 334
页数:9
相关论文
共 50 条
  • [31] Timing of sirolimus conversion influences recovery of renal function in liver transplant recipients.
    Rogers, Christin
    Johnson, Scott
    Gribbons, Megan
    Khwaja, Khalid
    Karp, Seth
    Egbuna, Cigo
    Mandelbrot, Dirtier
    Pavlakis, Martha
    Hanto, Douglas
    Curry, Michael
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 : 312 - 313
  • [32] Conversion between sirolimus and everolimus in heart transplant recipients
    Wert, Thomas J.
    Heeney, Stephanie
    Morrison, Maddy
    [J]. CLINICAL TRANSPLANTATION, 2023, 37 (11)
  • [33] Measured Renal Function in Pediatric Liver Transplant Recipients After Their Conversion From Tacrolimus to Sirolimus.
    Andrews, W.
    Hendrickson, R.
    Fioravanti, V.
    Fisher, R.
    Ricks, S.
    Daniel, J.
    [J]. TRANSPLANTATION, 2014, 98 : 717 - 717
  • [34] Changes in Immunophenotypes After Conversion from Calcineurin Inhibitors to mTOR Inhibitors in Renal Transplant Recipients
    Yildiz, A.
    Cavusoglu, M.
    Adin, S.
    Caliskan, Y.
    Ozkok, A.
    Tasci, H.
    Deniz, G.
    Sariyar, M.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15
  • [35] Measured Renal Function in Pediatric Liver Transplant Recipients After Their Conversion From Tacrolimus to Sirolimus.
    Andrews, W.
    Hendrickson, R.
    Fioravanti, V.
    Fisher, R.
    Ricks, S.
    Daniel, J.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 717 - 717
  • [36] Conversion From Calcineurin Inhibitors to Everolimus With Low-Dose Cyclosporine in Renal Transplant Recipients With Squamous Cell Carcinoma of the Skin
    Caroti, L.
    Zanazzi, M.
    Paudice, N.
    Tsalouchos, A.
    Carta, P.
    Larti, A.
    Pimpinelli, N.
    Moscarelli, L.
    Salvadori, M.
    Bertoni, E.
    [J]. TRANSPLANTATION PROCEEDINGS, 2012, 44 (07) : 1926 - 1927
  • [37] CONVERSION FROM CALCINEURIN INHIBITORS TO EVEROLIMUS RESULTED IN DECREASE OF SERUM TGF-BETA and URINARY NGAL IN RENAL TRANSPLANT RECIPIENTS
    Alpay, Nadir
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2013, 28 : 500 - 501
  • [38] Conversion to Everolimus in Kidney Transplant Recipients With Decreased Renal Function
    Inza, A.
    Balda, S.
    Alvarez, E.
    Zarraga, S.
    Gainza, F. J.
    Lampreabe, I.
    [J]. TRANSPLANTATION PROCEEDINGS, 2009, 41 (06) : 2134 - 2136
  • [39] The Efficacy and Limitations of Sirolimus Conversion in Liver Transplant Patients Who Develop Renal Dysfunction on Calcineurin Inhibitors
    Patrick Lam
    Atsushi Yoshida
    Kimberly Brown
    Marwan Abouljoud
    Iman Bajjoka
    Fadi Dagher
    Dilip K. Moonka
    [J]. Digestive Diseases and Sciences, 2004, 49 : 1029 - 1035
  • [40] Preserving Flow in Liver Transplant Recipients: mTOR Inhibitors Everolimus and Sirolimus Are Not Peas From a Pod
    Bhat, M.
    Charlton, M.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 (07) : 1633 - 1635